On-line bioaffinity Nanolc-MS Elapid venom profiling a b s t r a c t Venoms from snakes are rich sources of highly active proteins with potent affinity towards a variety of enzymes and receptors. Of the many distinct toxicities caused by envenomation, neurotoxicity plays an important role in the paralysis of prey by snakes as well as by venomous sea snails and insects. In order to improve the analytical discovery component of venom toxicity profiling, this paper describes the implementation of microfluidic high-resolution screening (HRS) to obtain neurotoxicity fingerprints from venoms that facilitates identification of the neurotoxic components of envenomation. To demonstrate this workflow, 47 snake venoms were profiled using the acetylcholine binding protein (AChBP) to mimic the target of neurotoxic proteins, in particular nicotinic acetylcholine receptors (nAChRs). In the microfluidic HRS system, nanoliquid chromatographic (nanoLC) separations were on-line connected to both AChBP profiling and parallel mass spectrometry (MS). For virtually all neurotoxic elapid snake venoms tested, we obtained bioactivity fingerprints showing major and minor bioactive zones containing masses consistent with three-finger toxins (3FTxs), whereas, viperid and colubrid venoms showed little or no detectable bioactivity. Our findings demonstrate that venom interactions with AChBP correlate with the severity of neurotoxicity observed following human envenoming by different snake species. We further, as proof of principle, characterized bioactive venom peptides from a viperid (Daboia russelli) and an elapid (Aspidelaps scutatus scutatus) snake by nanoLC-MS/MS, revealing that different toxin classes interact with the AChBP, and that this binding correlates with the inhibition of a7-nAChR in calcium-flux cell-based assays. The on-line post-column binding assay and subsequent toxin characterization methodologies described here provide a new in vitro analytic platform for rapidly investigating neurotoxic snake venom proteins.
Introduction
Many studies investigating the toxicity of individual venom components involve the initial activity screen of crude venoms followed by fractionation and re-screening of the fractions. Active fractions for the toxic effect under study are then structurally characterized, mainly by mass spectrometry (MS) based approaches. To characterize the full biological effect, relatively large quantities of toxins are needed, which are acquired by semipreparative purification, by production in recombinant protein production systems, or by peptide synthesis. The purified bioactives can also be used to study their effect on pharmaceutically relevant receptors or enzymes in venom-based drug discovery, which is a growing research field providing new drug-leads from venoms as natural sources (Casewell et al., 2013; Kini and Fox, 2013; Vetter et al., 2011; Vonk et al., 2011) .
High-throughput screening methods are desirable to rapidly assess bioactivity profiles of chosen venom toxicities. However, to investigate individual bioactives, a chromatographic separation of crude venom is still required prior to bioassaying in order to separate venom toxins with different, counteracting, and/or overlapping toxicities. As this is a costly and time-consuming endeavor for which large venom quantities are required, chromatographic analytics combining continuous flow post-column bioassays with parallel MS are an efficient alternative. These approaches, such as microfluidic high-resolution screening (HRS) , can be considered to directly measure fingerprint toxicity profiles of venoms. Microfluidic HRS uses nanoLC separations requiring very low sample quantities and is able to identify individual bioactives in on-line post column bioassay format, while parallel MS analysis directly allows accurate mass determination of the bioactives.
Recent studies using HRS methodology have focused on profiling venoms for drug discovery applications. The bioassay used in some of these studies was a fluorescence enhancement assay for AChBP profiling (Kool et al., 2010) . The AChBP is a stable structural homologue of the extracellular ligand binding domain of nicotinic acetylcholine receptors (nAChRs), in particular the a7-nAChR (Smit et al., 2001) , which has been widely used as an nAChR mimicking protein of nAChR relevant ligands (Bourne et al., 2014 (Bourne et al., , 2015 Brejc et al., 2002; Celie et al., 2005; Inserra et al., 2013; Lin et al., 2016; Shahsavar et al., 2016; Wan et al., 2015; Xu et al., 2017) . This implies that the AChBP could be used to profile neurotoxicity of individual venom components that target nAChRs. The a7-nAChR plays an important role in neuronal communication by converting neurotransmitter binding into electrical membrane depolarization. This receptor belongs to the family of the cys-loop ligand-gated ion channels (LGICs), and it combines binding sites for the neurotransmitter acetylcholine (ACh) and a cationic transmembrane ion channel (Albuquerque et al., 1997; Dani, 2001) . One recent study by Ratanabanangkoon et al. already demonstrated the potential of using nAChR mimicking AChBP for measuring elapid antivenom potency (Ratanabanangkoon et al., 2017) . In that study, Torpedo californica nAChR was utilized in a straightforward assay for testing antivenom generated against the elapid snake Naja kaouthia.
Here we demonstrate the potential of microfluidic HRS as a tool for obtaining neurotoxicity profiles of venoms based on the generic binding properties of neurotoxins to the nAChR mimic AChBP. These profiles can aid in research on neuropathological effects caused by specific neurotoxic peptides. In addition, this methodology could potentially be used to estimate the neurotoxic potency of venoms. Consequently, 47 venoms from the Elapidae, Viperidae and Colubridae snake families were screened with microfluidic HRS to obtain fingerprint profiles of individual bioactive compounds binding to Lymnea stagnalis (Ls) AChBP. These measurements were then sorted according to snake families, from which neurotoxicity profiles were compared. To demonstrate optional subsequent characterization of the selected bioactives, several venom toxins were purified followed by structural (i.e., full toxin identification) and biological characterization. For this, proteomic analysis and fluorescent imaging plate reader (FLIPR)-based assays containing mammalian cells over-expressing the a7-nAChR were performed.
Materials and methods

Chemicals and biological reagents
The mobile phases for nanoLC separation were prepared from nanoLC-MS grade 99.97% acetonitrile (ACN), 99.95% trifluoroacetic acid (TFA) and 99.95% formic acid (FA) obtained from Biosolve (Valkenswaard, the Netherlands). High-performance liquid chromatography (HPLC) grade water was produced by a Milli-Q purification system from Millipore (Amsterdam, the Netherlands). LsAChBP (from snail species Lymnaea stagnalis) was expressed and purified from Baculovirus using the pFastbac I vector in Sf9 insect cells as described elsewhere (Celie et al., 2005) . (E)-3-(3-(4-diethylamino-2-hydroxybenzylidene)-3,4,5,6-tetrahydropyridin-2-yl)pyridine (DAHBA) was synthesized in house (Kool et al., 2010) . Ammonium bicarbonate, sequencing grade trypsin and Glu-C were obtained from Sigma-Aldrich (Zwijndrecht, The Netherlands). Nicotine was obtained from Tocris Biosciences (Bristol, United Kingdom).
Snake venom samples
Venoms from the following species were profiled in this study: Acanthophis antarcticus, Acanthophis praelongus, Acanthophis pyrrhus, Agkistrodon contortrix contortrix, Agkistrodon contortrix laticinctus, Agkistrodon contortrix mokasen, Agkistrodon bilineatus bilineatus, Agkistrodon piscivorus conanti, Agkistrodon piscivorus piscivorus, Aspidelaps scutatus scutatus, Atheris squamigera, Atropoides mexicanus, Bitis arietans, Bitis gabonica "rhinoceros", Bitis nasicornis, Boiga dendrophila, Boiga irregularis, Bothrops alternatus, Bothrops atrox, Bungarus caeruleus, Calloselasma rhodostoma, Causus rhombeatus, Cerastes cerastes, Crotalus adamanteus, Crotalus atrox, Crotalus basiliscus, Crotalus durissus culminatus, Crotalus durissus cumanensis, Crotalus durissus terrificus, Crotalus durissus vegrandis, Crotalus adamanteus, Crotalus horridus, Crotalus horridus "atricaudatus", Crotalus ruber ruber, Crotalus viridis viridis, Daboia russelii, Dendroaspis polylepis, Dendroaspis viridis, Echis carinatus sochureki, Gloydius blomhoffi, Oxyuranus microlepidotus, Pseudechis australis, Pseudechis porphyriacus, Pseudonaja affinis, Pseudonaja inframacula, Pseudonaja nuchalis, Pseudonaja textilis. Most snake venoms were obtained commercially from Kentucky Reptile Zoo (City?, USA), Ventoxin (City?, USA), Biotoxin (City?, USA), Venom Supplies (Tanunda, Australia) and African Reptiles & Venoms (Johannesburg, South Africa). The Boiga irregularis and Gloydius blomhoffii venoms were kind gifts from Prof. Steve Mackessy (University of Northern Colorado, USA) and Prof. Sadaaki Iwanaga (Kyushu University, Japan), respectively. In case venom of a single animal is used, its major toxins will most likely be present regardless of the geographical location of the snake and/or when the venom was extracted, and/or if venom extraction was from a snake held in captivity or from the wild. Still, individual toxin quantities obtained per snake milking can vary due to these factors and therefore conclusions have to be drawn cautiously. Many of the venoms used, however, were not from a single animal. They are pools purchased commercially or provided by us and by others. In this case, the pooling of venom from multiple extractions of multiple individuals (possibly from different phylogenetic backgrounds and geographical locales) should account for this concern. Lyophilized venoms were kept at À20 C. The venom samples were dissolved in Milli-Q water/ACN/TFA 95:5:0.1% to a final concentration of 10 mg/ ml. Before microfluidic HRS screening, the venom samples were spiked with a final concentration of 2 mM nicotine which was used as an internal standard allowing correlation of bioactivity peaks to ions (m/z values) of the bioactives observed in MS. After analysis, the remainder of dissolved venom samples were stored at À20 C for further use.
Microfluidic HRS screening system
The microfluidic HRS was performed using the system as described previously . In short, the system comprised three distinct parts: 1) nanoLC for separation of the venom peptides and proteins in the crude venoms followed by a post-column one to one split to 2) nanoESI-MS for accurate mass determination of eluting peptides and proteins, and to 3) the online microfluidic bioassay for AChBP bioactivity. The internal standard nicotine (which binds to AChBP) was spiked in venom samples to correlate the bioactivity peaks to corresponding m/z values of the bioactive negative peaks. This internal standard eluted at the column dead time and allowed accurate assessment of the lag time between the bioassay response and the MS response. The m/z values obtained for components from microfluidic HRS data assisted optional subsequent purification and characterization of bioactives using MS-guided LC fractionation. Netherlands) ion-trapetime-of-flight (ITeTOF) hybrid mass spectrometer equipped with a Picoview nanoESI source from New Objective (Woburn, MA, USA) was used for MS detection in the HRS screening setup. The nanoESI-MS operating conditions were as described previously . 3. On-line microfluidic AChBP bioassay: The on-line microfluidic bioassay part of the HRS screening setup was operated as described previously . For the on-line bioassay the following conditions were used: 5 nM Ls-AChBP and 15 nM DAHBA dissolved in a buffer consisting of 1 mM KH 2 PO 4 , 3 mM Na 2 HPO 4 , 0.16 mM NaCl and 20 mM trizma base/HCl (pH 7.5) and containing 400 mg/mL ELISA Blocking Reagent. This on-line microfluidic biochemical assay was performed in a microfluidic chip for which a bioassay mixture containing AChBP 5 nM and tracer molecule DAHBA 15 nM was continuously infused by a syringe pump at 5 mL/min where the solution was mixed with nanoLC effluent running at 200 nL/min.
Overview of the full screening workflow
The profiling of venoms included in this study was performed with the same microfluidic HRS gradient as described by Heus et al. (2013) . After matching bioactivity peaks to their identities (i.e., m/z values), we selected several bioactive toxins for further characterization. These bioactives were then purified using normal-bore MSguided LC fractionation (see next section), which was done after confirming the bioactivity of the purified toxins by rapid rescreening in the microfluidic HRS system. Large-scale purification could optionally be performed in order to obtain sufficient amount of toxin for full chemical (i.e., identification of the protein sequence by proteomic approaches) and biological (i.e., human a7-nAChR functional activity) characterization.
Peptide purification approaches
MS-guided LC fractionation: Small-scale purification of selected bioactive peptides was performed by MS-guided LC fractionation as described previously (Heus et al., 2014; Otvos et al., 2013) . This was repeated six times for each of the selected venoms from which the proteins were to be purified. This yielded estimated sub-milligram material of each purified toxin. The purified toxin fractions were then vacuum evaporated at room temperature using a Centrivap vacuum centrifuge and then stored at À20 C until re-screening with the microfluidic HRS system. These purified toxins can be used for proteomics-based structural identification, and for rescreening using the microfluidic HRS system to confirm bioactivity after purification.
Preparative purification: An € Akta Purifier HPLC system (GE Healthcare, Uppsala, Sweden), equipped with automatic fraction collector was used for preparative purification of the selected bioactive toxins. Approximately 50 mg of crude Daboia russelli and Aspidelaps scutatus scutatus venoms were fractionated separately on a pre-equilibrated Hiload 16/600 Superdex 75 prep grade column (1 Â 120 ml bed volume) under isocratic conditions at a flowrate of 1 mL/min. Tris-HCl (50 mM, pH 7.4) was used as elution buffer. An LCQ fleet Ion Trap MS equipped with ESI source (Thermo Scientific, MA, USA) was used to confirm the collected fractions containing the m/z of the bioactive protein(s). The MS operating conditions comprised an electrospray voltage of 4.4 kV in positiveion mode with recording in the mass range of m/z 50e2000. Fractions containing the bioactive peptides were pooled and fractionated on a Phenomenex Jupiter C18 column (3 mm, 300 Å, 4.6 Â 250 mm) with gradient elution. Eluent A contained MilliQwater with 0.1% TFA and eluent B was MilliQ-water/ACN/TFA 20:80:0.1 (v/v). After the purity of the fractions was confirmed by MS to be >95%, these fractions were pooled, freeze-dried and stored at À20 C until further use. The molecular masses of bioactive toxins purified from D. russelii were 13907 and 13664 Da. The molecular masses of bioactive toxins purified from A. s. scutatus were 7184, 7680, 7008 and 7136 Da. The amounts purified using this preparative approach allow proteomics-based structural identification and re-screening using the microfluidic HRS system, but also full biological characterization (i.e., plate reader based AChBP affinity determination and functional activity on the a7-nAChR).
Proteomics characterization of purified toxins
Proteomics techniques were used to determine the amino acid sequences of the purified bioactive proteins. Reduction and alkylation of the purified venom toxins were performed prior to enzymatic digestion as described previously (Hale et al., 2004) . Alkylation and reduction was performed by incubating the bioactives at 37 C for 2 h with 130 mM iodoethanol and 17 mM triethylphosphene. After incubation, the solvents were evaporated and the reduced and alkylated proteins were re-dissolved in 50 mM ammonium bicarbonate buffer (pH 8.4) and incubated with trypsin and Glu-C, added at an estimated ratio of 100:1 w/w (protein:protease) for 24 h at 24 C. After the enzymatic digestions, the trypsin and Glu-C were deactivated with FA using a final volume of 1% compared to the total volume. Peptide sequence analyses were performed by MS/MS using a Triple TOF 5600 system (AB Sciex, Framingham, MA) operating in positive-ion mode. The proteomics data obtained were analyzed with Mascot software from Matrix Science.
Cell culture and FLIPR experiments
The fluorescent imaging plate reader (FLIPR) (Molecular Devices, Sunnyvale, CA, USA) functional calcium-flux assays were performed as described previously (Cardoso et al., 2015) . Human neuroblastoma SH-SY5Y cells endogenously expressing the a7-nAChR were cultured in T175 flasks using Roswell Park Memorial Institute (RPMI) medium supplemented with 2 mM L-glutamine and 15% fetal bovine serum (FBS) in a 37 C incubator at 5% CO 2 . Two days before Ca 2þ -flux assays, cells were detached from the culture flasks using 0.25% trypsin/EDTA, seeded at 40 mL per well of a 1 Â 10 6 cells/ml suspension in black walled clear flat bottom 348-well plates (Corning Life Technologies, NY, USA) and incubated at 37 C and 5% CO 2 for 48 h. The assay buffer used for preparing the reagents consisted of 140 mM NaCl, 11.5 mM glucose, 5.9 mM KCl, 1.4 mM MgCl 2 , 1.2 mM NaH 2 PO 4 , 5 mM NaHCO 3 , 1.8 mM CaCl 2 , and 10 mM HEPES (pH 7.4). Cells were loaded and incubated at 37 C and 5% CO 2 for 30 min with Calcium 4 dye at a concentration according to the manufacturer (Molecular Devices, Sunnyvale, CA) and with
, an a7 agonist, at a 20 mM final concentration. Fluorescence responses were recorded on excitation wavelengths of 470e495 nm and emission wavelengths of 515e575 nm. For obtaining an agonist signal, 30 mM choline was used, and 30 mM tubocurarine was used as antagonist control.
Results and discussion
Venom profiling for toxins with AChBP-binding affinity
In total, bioactivity fingerprint chromatograms of 47 snake venoms were included in this study for evaluating the potential of using AChBP affinity as an indicator of neurotoxicity. Of these, 42 venoms were measured during this study and five were previously analyzed using the same analytical technique of which the results have been reported Otvos et al., 2013) . Fig. 1 shows a typical result obtained using the microfluidic HRS system from profiling Bungarus caeruleus venom. In Fig. 2 , similar results are depicted for other elapid snake venoms showing major bioactivity peaks. From the 47 venoms, 15 venoms contained high affinity/abundant bioactives, eight venoms showed medium and/or low affinity/abundant AChBP ligands, and for the rest of the venoms no bioactivity peaks were detected. Accurate masses for bioactive compounds binding to AChBP were obtained using the parallel acquired MS data. Table 1 displays the bioactives detected.
The profiling results identified only elapid snake venoms as highly neurotoxic, based on the extent of negative (i.e. bioactive) peaks observed following venom interactions with the nAChR mimic AChBP (Table 1 ). The total bioactivity can be qualitatively assessed from the negative peak height in combination with peak width, and the number of negative peaks observed in a bioactivity chromatogram. In some cases, the signal did not return to the baseline level after elution of a neurotoxic AChBP binder, as observed for the elapid snakes Acanthophis antarcticus, Acanthophis pyrrhus, Pseudonaja nuchalis and Dendroaspis polylepis (Fig. 2) . These results are indicative of the presence of one or more highaffinity binders to AChBP, potentially in combination with eluting neurotoxic peptides that adhere to the walls of the microfluidic reaction coil causing delayed responses. In these cases, subsequent analyses were only conducted after the baseline had returned to normal, which in some cases could take up to several hours. For the bioactives/binders, it was observed that all elapid peptides identified are in the molecular weight (MW) range of 6000e8000 Da, suggestive of 3FTx neurotoxins. For the relatively few viperid bioactives/binders observed, MW ranges of 13000e14000 are characteristic for neurotoxic phospholipases A 2 (PLA 2 s) ( Table 1) . Interactions of PLA 2 s with AChBP have previously been described by Vulfius et al. (2011; .
Using the applied bioassay, no bioactives were found in the following viperid venoms: Agkistrodon bilineatus bilineatus, Agkistrodon piscivorus conanti, Agkistrodon piscivorus piscivorus, Atheris squamigera, Atropoides mexicanus, Bitis arietans, Bitis gabonica "rhinoceros", Bitis nasicornis, Bothrops alternatus, Bothrops atrox, Calloselasma rhodostoma, Causus rhombeatus, Cerastes cerastes, Crotalus adamanteus, Crotalus atrox, Crotalus durissus culminatus, Crotalus duissus cumanensis, Crotalus horridus, Crotalus horridus "atricaudatus", Crotalus ruber ruber, Crotalus viridis viridis, Echis carinatus sochureki and Gloydius blomhoffi. In addition, we found no bioactives in the venom of the colubrid snakes Boiga dendrophila and B. irregularis. For the latter two snake species, the nAChR ligands denmotoxin and irditoxin have been described (Pawlak et al., 2006 (Pawlak et al., , 2009 . However, these studies describe for both denmotoxin and irditoxin highly bird-specific postsynaptic activity. Irditoxin showed a potent neuromuscular blockade at the avian neuromuscular junction which was three orders of magnitude less effective at the mammalian neuromuscular junction, and as a consequence non-toxic to mice.
Thus, in general, we find that venoms containing components of major bioactivity were sourced from snakes that are known to cause potent neurotoxicity in case of human envenomation. This indicates that the use of AChBP for ligand screening, at least partly, captures venom toxins that likely cause medically important neurotoxicity in humans. Some of the snake nAChR ligands can . The online biochemical assay was performed in a microfluidic chip for which bioassay solution containing AChBP and tracer molecule DAHBA were infused continuously by a syringe pump and mixed with the nanoLC effluent. The chip's outlet was hyphenated to a microfluidic fluorescence detector for readout. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 2. Bioactivity profiles of (A) Dendroaspis polylepis, (B) Pseudonaja nuchalis, (C) Acanthophis antarcticus, (D) Acanthophis pyrrhus, (E) Pseudonaja inframacula and (F) Oxyranus microlepidotus.
Table 1
Overview of peptide and protein m/z values and masses observed in the venoms identified as binding to AChBP. Bioactivity is observed as negative signal in the chromatographic AChBP bioassay. Depending on the signal observed bioactives are classified as potential high or low affinity ligands (i.e., assigned as having minor, medium or major bioactivity). (Fig. S4) Elapidae No reports of neurotoxicity following envenoming (Churchman et al., 2010) 38 no corresponding mass e Minor Daboia russelii (Fig. 3b) Viperidae Neurotoxic envenoming common in parts of its range. Neurotoxins present in the venom (Silva et al., 2016 (Silva et al., , 2017 Warrell, 1995) (Kesters et al., 2013; Otvos et al., 2015; Smit et al., 2001 ). Therefore, it may be a useful in vitro tool for characterizing specific neurotoxins in the wider context of venom neurotoxicity. Major bioactives recovered from highly neurotoxic venoms include the species Bungarus caeruleus, Dendroaspis polylepis and Oxyuranus microlepidotus characterized here, and those previously described ) (Naja nivea, N. annulifera and D. jamesoni kaimosae) (Table 1) . Moreover, in general, the venoms that yielded only minor bioactives are also known or suspected to cause neurotoxicity in envenomed victims (Table 1) , but not to the same degree as those venoms that yielded major bioactive components. There are, however, a number of exceptions to this general trend: (i) a major bioactive was previously recovered from the primarily cytotoxic venom of N. mossambica (WHO, 2010) , (ii) the three Pseudonaja species screened here yielded major bioactive compounds despite neurotoxicity being clinically uncommon in bites by these species (White, 1995) , (iii) venom of three Agkistrodon species yielded minor bioactive components although these are not known to cause neurotoxicity in humans, and (iv) minor bioactive constituents were found in some North American rattlesnake species (e.g. Crotalus basiliscus and C. durissus vegrandis), but for others known to contain neurotoxins (e.g. C. d. culminatus, C. d. cumanensis and C. horridus) (Dowell et al., 2016) no bioactivity was detected. These discrepancies are potentially the result of the fact that snake venoms may consist of multiple isoforms of neurotoxins (such as 3FTxs and PLA 2 s) that target distinct receptors at the neuromuscular junction (Casewell et al., 2013) . Thus, while the use of AChBP in this study reveals bioactives that presumably interact with nAChRs, neurotoxins interacting with other receptors and channels are, understandably, not captured by this approach. The full interplay of ligands binding to different receptors resulting in eventual clinical neurotoxicity symptoms is not reflected by AChBP alone, but by a combination of different receptors. The current study is a first attempt to correlate clinical neurotoxicity with severity of ligands binding to AChBP. Indeed, some correlations were observed in this study. However, additional targets would need to be included to obtain a more complete picture and/or to get a better correlation of clinical neurotoxicity and toxin binding to the various different receptors involved. Future research in which similar assays are developed for other relevant receptors, and then applied to a snake venom screening campaign, would be a valuable approach to provide a more comprehensive correlation between neurotoxic compounds binding to receptors and clinical symptoms. Despite the inherent limitation of the method associated with the complexity of biological mixtures, we note that of all elapid snake venoms included in this study, only two failed to yield a major or minor bioactive component that interacted with AChBP. For one of these species, Pseudechis australis, this result correlates with the findings of Georgieva et al. who identified venom PLA 2 myotoxins and metalloproteases as the major components responsible for venom toxicity (Georgieva et al., 2011a) , and those of Johnston et al. who found no evidence of neurotoxicity in a cohort of envenomed snakebite victims (Johnston et al., 2013) . The case of Pseudonaja textilis is more complex, as this species is known to contain neurotoxins (Georgieva et al., 2011b) , although systemic neurotoxicity rarely presents in victims bitten by this species (Isbister, 2006) . The main protein responsible for the neurotoxicity of P. textilis is not a 3FTx, but a 623 amino acid large protein consisting of 5 subunits named textilotoxin, which binds to nAChRs both post-and presynaptically (Pearson et al., 1993) . We hypothesize that the absence of this bioactive in our screening experiments is due to this multi-subunit protein degrades under the conditions used for the nanoLC C18 separations. To test this hypothesis we performed flow injection analyses (FIA; which employs removing the analytical column from the system in order to allow injected venoms to be directly infused into the bioassay) of crude venom under non-denaturing conditions using buffer as eluent. Under these conditions we found a major bioactivity peak, and thus we conclude that the neurotoxic protein(s) of P. textilis denaturated on the nanoLC C18 column. These results indicate that for large MW neurotoxins and/or neurotoxins constituted of several subunits, denaturation and/or dissociation of complexes can, and will, likely yield false negatives. For 3FTxs, it is known that generally they keep their active configuration during C18 LC separations.
Venoms containing Major bioactives
In summary, our microfluidic HRS results revealed reasonable correlations between the bioactives recovered from each venom and the "severity" of neurotoxicity caused by those venoms. The microfluidic HRS methodology clearly is an asset in the initial assessment of the neurotoxic properties of snake venoms. However, it has to be noted that the methodology is not limited to snake venoms only but is also applicable to profiling venoms from other animals anticipated to interact with nAChRs, including cone snails, spiders, scorpions and others. Typical injection volumes between 50 and 500 nl are being used allowing analysis of venoms only available in very low volumes. As the configuration of the typical sample vials used requires larger volumes in order to allow successful and complete sample aspiration, an estimated 2e5 ml sample (non-diluted venom) would be the minimum. This would still enable analysis of venoms available in only very small amounts (e.g. from small venomous invertebrates)." In addition, it directly provides information on the number of neurotoxic components likely acting on nAChRs, and the individual contribution to the total neurotoxicity observed. Finally, accurate masses of the neurotoxic peptides are provided which facilitates neurotoxin classification (i.e., 3FTxs or PLA 2 s), and this process provides a valuable first-step prior to the full characterization of neurotoxins of interest, via MSguided LC fractionation.
3.2. Demonstration of full structural and biological characterization of selected neurotoxic peptides after MS-guided LC fractionation Fig. 3 depicts the analytical workflow for MS-guided LC fractionation and characterization, from the initial microfluidic HRS measurements to the full structural and biological characterization of selected bioactive toxins. Using the microfluidic HRS system, venoms were first profiled, and those containing bioactives were selected. An advantage of this approach is that low-affinity or lowconcentration bioactives can be identified in the presence of highly active and/or abundant bioactives. Next, the selected venoms were processed using straightforward MS-guided LC fractionation of the bioactives, followed by rescreening of the purified bioactives with the microfluidic HRS system to confirm bioactivity. The purified bioactives were then studied with proteomic tools to obtain their full structural identity. A last additional feature of the workflow involved eventual preparative purification of bioactives for assessing their biological profile using an a7-nAChR functional calcium-flux assay.
From the microfluidic HRS data, two venoms were selected to demonstrate structural identification of selected neurotoxic peptides. The elapid Aspidelaps scutatus scutatus (shield-nose snake) and the viperid Daboia russelii (Russell's viper) were chosen, because (i) their venom gave unexpected bioaffinity responses in the microfluidic HRS analysis, and (ii) the lack of prior research relating to their venom interacting with AChBP and/or nAChRs. Fig. 4 displays the bioactivity profiles of A. s. scutatus (Fig. 4A ) and D. russelii (Fig. 4B) venom with the TICs, and XICs corresponding to the bioactive negative peaks observed. From the venom of A. s. scutatus, two bioactives were selected for further biochemical characterization: a bioactive correlated to the most abundant ion with m/z 1197.4096 (6þ) (MW 7178.4576 Da) and a bioactive with the most abundant ion with m/z 1279.7692 (6þ) (MW 7672.6152 Da) . From the venom of D. russelii, a bioactive correlated to the most abundant ion with m/z 1739.3901 (8þ) (MW 13907.1208 Da) was selected.
The bioactives from the selected snake venoms were purified using MS-guided LC fractionation in order to obtain small quantities of purified toxins. From the venom of D. russelii, the most abundant ion with m/z 1739.3901 (8þ) (MW 13907.1208 Da) was traced during LC separation for purification of the selected peptide. From the venom of A. s. scutatus, the ions with m/z 1197.4096 (6þ) (MW 7178.4576 Da) and m/z 1279.7692 (6þ) (MW 7672.6152 Da) were traced for purification. The three purified toxins were first reanalyzed with the microfluidic HRS, which in both cases confirmed AChBP bioactivity of the toxins, while the parallel obtained MS data revealed a purity of >95% (relative signal measured by MS) for all toxins.
The purified toxins were subsequently submitted to proteomic analysis using standard reduction, alkylation, and digestion protocols with trypsin and glu-C. After measurement of the digests using nanoLC-TripleTOF MS, peptide sequence analysis was performed by database searching using MASCOT and the Swiss-Prot/ UniProt database. For D. russelli, the results annotated the bioactive toxin as a PLA 2 , with the highest hit from the Swiss-Prot/ Fig. 3. A) The MS-guided workflow for bioactive characterization. First, an initial analysis using the microfluidic HRS is performed. The parallel acquired MS data is compared with the negative bioactivity peaks in the chromatographic bioassay from which the matching (peak shape and retention time) ions are retrieved as shown in (B). Using these indicative ions, the respective bioactive toxins can be purified using MS-guided LC fractionation allowing characterization with proteomics approaches, and/or re-screening with microfluidic HRS. For full biological characterization, however, sufficient material needs to be purified using traditional preparative purification. UniProt database yielding a protein score of 215, sequence coverage of 30% and annotated as the basic PLA 2 'RV-4'. This particular PLA 2 is known from Daboia siamensis venom, but no hits were found for PLA 2 s described from the venom of D. russelli, which makes it likely that this compound is a novel ortholog. Additional BLAST searches of peptides recovered from the digested purified toxin confirmed this compound is not known from D. russelli venom. For A. s. scutatus, one of the peptides purified (with the most abundant ion with m/z 1197.4096 (6þ)) was annotated as Cytotoxin homolog S4C8 (UniProt code P19004) with a sequence coverage of 81%. The second peptide purified (with most abundant ion with m/z 1279.7692 (6þ)) most closely related to Long neurotoxin 1 (UniProt code P25670) with a sequence coverage of 34%. Additional BLAST searches confirmed that the detected peptide sequences of the two purified toxins of A. s. scutatus match Cytotoxin homolog S4C8 and Long neurotoxin 1; both of which are members of the 3FTx toxin family.
When full biological characterization of a structurally identified toxin is required, a preparative scale purification should be performed to obtain sufficient material to conduct the necessary experiments such as the actual binding/activation/modulation effects on the a7-nAChR. In this last part of the workflow, traditional purification was utilized for the basic PLA 2 RV-4 (MW 13907.1208 Da) from D. russelli, and Cytotoxin homolog S4C8 (MW 7178.4576 Da) and Long neurotoxin 1 (MW 7672.6152 Da) from A. s. scutatus.
These purified toxins were then tested on a functional calcium-flux assay using SH-SY5Y cells endogenously expressing the a7-nAChR, with a FLIPR setup in agonist activation mode for measuring antagonists. The PLA 2 from D. russelli caused cell lysis (the cells were visually lysed as observed under a microscope). For this assay, extremely low potency inhibition of the functional response on the FLIPR assay was observed, with IC 50 value of 5 ± 7 mM, but this could fully or in part be the result of cell lysis. To reduce the potential effect of cell lysis, a subsequent FLIPR assay was performed using a shorter pre-incubation time (i.e. 2 instead of 10 min), which also showed inhibition of the functional response, but with an even higher IC 50 value. The binding affinities of cytotoxin homolog S4C8 and the Long neurotoxin 1 from A. s. scutatus for the a7-nAChR was also confirmed in the functional assay, with IC 50 values of 28 ± 4 mM and 0.4 ± 0.3 nM, respectively. The Long neurotoxin 1 was expected to be a potent inhibitor of nAChRs as these types of toxins are known to bind to nAChRs with high affinity (in particular to the a7-nAChR), but binding affinity of the cytotoxin homolog S4C8 for a7-nAChR has to our knowledge not been described previously. Although the current methodology shows some correlations between assay response and reports of clinical neurotoxicity, the methodology mainly profiles binders for a7 receptors, such as longchain alpha-neurotoxins. A more comprehensive picture would likely be obtained if additional screening of other proteins that mimic different receptors involved in neurotoxicity were also included. An example would be to include screening for activity on muscle nAChRs using muscle nAChR-like Torpedo nAChRs. However, such work is beyond the scope of this study.
Conclusion
This research demonstrates the potential of using microfluidic HRS for rapidly generating neurotoxicity fingerprints of venoms. By profiling snake venoms bioaffinity to AChBP directly after chromatographic separation we correlate neurotoxicity profiles with the severity of envenomation neurotoxicity. Evidently, such profiles are inherently influenced by the differential affinity of AChBP for neurotoxins that likely interact with nAChRs. Nonetheless, the approach described here provides a new, high throughput, in vitro screening strategy for characterizing elements of neurotoxicity caused by snake venoms. Furthermore, we demonstrate that our workflow can be extended to include full structural identification and biological assessment of resulting bioactive venom toxins. Using two venoms as a proof of principle, we show that the AChBP is an effective mimic for nAChRs, as purified bioactives inhibit a7-nAChR in functional assays.
